Morgan Stanley initiated coverage of Omada Health (OMDA) with an Overweight rating and $25 price target Omada Health is becoming an integral solution to drive adherence in treating obesity, diabetes and hypertension, large markets impacting more than 120 million people, the analyst tells investors in a research note. Revenue upside and AI automation should drive margins higher, a key catalyst for multiple expansion, the firm says.
Don’t Miss TipRanks’ Half-Year Sale
1
Source: tipranks.com
